Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: The glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2466-2474

  Lonn, Eva M ^a,b   Bosch, Jackie ^b   Diaz, Rafael ^c   Lopez Jaramillo, Patricio ^d   Ramachandran, Ambady ^e   Hâncu, Nicolae ^f   Hanefeld, Markolf ^g   Krum, Henry ^h   Ryden, Lars ⁱ   Smith, Sandra ^b   McQueen, Matthew J ^b   Dyal, Leanne ^b   Yusuf, Salim ^a,b   Gerstein, Hertzel C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario   (Argentina)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e Research Foundation   (India)

^f IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h MONASH UNIVERSITY   (Australia)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; GLUCOSE; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; INSULIN GLARGINE; LIPID; OMEGA 3 ACID ETHYL ESTER; PLACEBO;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY BIFURCATION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSGLYCEMIA; FEMALE; FOLLOW UP; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INTRAVASCULAR ULTRASOUND; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; CAROTID INTIMA-MEDIA THICKNESS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84883822868     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2129     Document Type: Article

References (41)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364: 829-841
2. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362: 800-811
3. Gerstein HC, Islam S, Anand S, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15, 780 patients from the INTERHEART study. Diabetologia 2010; 53: 2509-2517
4. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375: 2215-2222
5. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14: 575-585
6. Muntoni S, Muntoni S, Draznin B. Effects of chronic hyperinsulinemia in insulinresistant patients. Curr Diab Rep 2008;8: 233-238
7. Nandish S, Bailon O, Wyatt J, et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep 2011;13: 123-128
8. Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010; 376: 540-550
9. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312: 1205-1209
10. Dolecek TA, Granditis G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 1991;66: 205-216
11. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort. AmJ Epidemiol 2007; 165: 617-624
12. Sekikawa A, Curb JD, Ueshima H, et al.; ERA JUMP (Electron-Beam Tomography, Risk Factor Assessment Among Japanese and U.S. Men in the Post-World War II Birth Cohort) Study Group.Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008;52: 417-424
13. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757-761
14. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto. miocardico Lancet 1999;354: 447-455
15. Yokoyama M, Origasa H, Matsuzaki M, et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369: 1090-1098
16. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and metaanalysis. JAMA 2012;308: 1024-1033
17. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC; HARP Research Group. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995; 25: 1492-1498
18. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361: 477-485
19. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130: 554-562
20. Angerer P, Kothny W, Störk S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res 2002;54: 183-190
21. Hjerkinn EM, Abdelnoor M, Breivik L, et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2006;13: 325-333
22. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155:26-32
23. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367: 319-328
24. Bosch J, Gerstein HC, Dagenais GR, et al.; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367: 309-318
25. Lonn EM, Gerstein HC, Sheridan P, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009;53: 2028-2035
26. Lonn E, Yusuf S, Dzavik V, et al.; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103: 919-925
27. Crouse JR, 3rd, Raichlen JS, Riley WA, et al.; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297: 1344-1353
28. Kastelein JJ, van Leuven SI, Burgess L, et al.; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356: 1620-1630
29. Bots ML, Visseren FL, Evans GW, et al.; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370: 153-160
30. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003; 34: 2985-2994
31. Dogan S, Kastelein JJ, Grobbee DE, Bots ML. Mean common or mean maximum carotid intima-media thickness as primary outcome in lipid-modifying intervention studies. J Atheroscler Thromb 2011;18: 946-957
32. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes [Internet], December 2008. Available from www.fda.gov/downloads/ Drugs/.../Guidances/ucm071627.pdf. Accessed October 2012
33. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004;109: 849-854
34. Vehkavaara S, Yki-Järvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24: 325-330
35. Taskinen MR, Kuusi T, Helve E, Nikkilä EA, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8: 168-177
36. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
37. Brohall G, Odén A, Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 2006;23: 609-616
38. Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008;7:16
39. Joya-Galeana J, Fernandez M, Cervera A, et al. Effects of insulin and oral antidiabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev 2011;27: 373-382
40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577-1589
41. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169